Form 4 Filing for Evogene Ltd. - Nimrodi Nir

This filing reports a transaction by Nimrodi Nir, a director at Evogene Ltd. On September 4, 2026, 10,000 stock options to purchase Ordinary Shares were granted with an exercise price of $0.58 per share. These options vest quarterly, with full vesting expected by September 4, 2027. The footnote indicates this is part of the Issuer's 2021 Share Incentive Plan. The filing also includes a Power of Attorney document authorizing Nitsan Deutsch to act on behalf of the reporting person for SEC filings.